article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine

Pharmaceutical Technology

The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. billion and $812 million in 2028. Competition in an increasingly heated market. VAX-24 has forecasted sales of $21 million in the same year. Further plans in the making.

article thumbnail

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

By this same virtue, PROTACs are able to degrade previously undruggable targets, which provides a major competitive advantage for this modality if shown to be true. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. with Calquence, 16% with Imbruvica, NCT02477696).

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. The potential increase in industry competition could also spell trouble for some. Now, the demand for such equipment is on track to grow exponentially.

Medical 98
article thumbnail

Five potential EU regulatory changes impacting the life sciences industry in 2023

European Pharmaceutical Review

In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. However, a delicate balance will need to be struck between the need for affordable and accessible medicinal products and the desire to foster innovation and competitiveness in the EU.

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. The potential increase in industry competition could also spell trouble for some. Now, the demand for such equipment is on track to grow exponentially.

Medical 52